United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
| Key metrics | Actual |
|---|
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for ZyVersa Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Forecast |
|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|
| Total Assets | $347,901.00 | $246,123.00 | $246,123.00 | $246,123.00 | $246,123.00 | $246,123.00 |
|---|---|---|---|---|---|---|
| Net Income | -$24,952,378.00 | -$24,712,749.33 | -$24,679,135.16 | -$24,682,506.64 | -$24,696,481.54 | -$24,756,594.04 |
| Sector average | $125,199,974.66 | -$3,170,058,355.52 | -$23,486,545,336.74 | -$23,692,765,651.74 | -$23,918,648,675.89 | -$24,600,837,952.53 |